Direct thrombin inhibitors: current status and future prospects

Bibliography

• TAKADA, AKIKAZU; TAKADA, YUMIKO; URANO, TETSUMEI: The physiological aspects of fibrinolysis. Thromb. Res. (1994) 76(1):1–31.
   PubMed Web of Science ®Google Scholar
• TALBOT MD, BUTLER KD: Potential clinical uses of thrombin inhibitors. Drug News Perspect. (1990) 3 (6):357–363.
   Google Scholar
• TRACY PB: Regulation of thrombin generation at cell surfaces. Semin. Thromb. Hemostasis (1988) 14 (3):227–233.
   PubMed Web of Science ®Google Scholar
• FENTON JW, II: Regulation of thrombin generation and functions. Semin. Thromb. Hemostasis (1988) 14 (3):234–240.
   PubMed Web of Science ®Google Scholar
• LAMMLE B, GRIFFIN JH: Formation of the fibrin clot: thebalance of procoagulant and inhibitory factors. Clin. Haematol (1985) 14(2):281–342.
   PubMedGoogle Scholar
• VU TKH, HUNG DT, WHEATON VI et al: Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell (1991) 64 (6): 1057–1068 .
   PubMed Web of Science ®Google Scholar
• MONCADA S: Prostacyclin - discovery and biological importance. In: Prostaglandins: Res. Clin. Update. GL Longenecker SW Schaffer (Eds.), Alpha Ed., Minneapolis, Minn, USA (1985):1–39.
   Google Scholar
• TURPIE AGG, WEITZ JI, HIRSH J: Advances in antithrom-botic therapy: novel agents. Thromb. Haemostasis (1995) 74 (1):565–571.
   PubMed Web of Science ®Google Scholar
• FENTON JAN II, OFOSU FA, MOON DG, MARAGANORE JM: Thrombin structure and function: why thrombin is the primary target for antithrombotics. Blood Coag. Fibrinolysis (1991) 2(0:69–75.
   PubMedGoogle Scholar
• •Reviews thrombin as a therapeutic target.
   Google Scholar
• MENEAR KA: Progress Towards the Discovery of Orally Active Thrombin Inhibitors. Current Medicinal Chemistry. (1998) 5:457–468.
   PubMed Web of Science ®Google Scholar
• HIRSH J: Heparins. Fibrinolysis (1995) 9 (Suppl. 1):66–68
   Google Scholar
• AMMAR HO; GHORAB M; EL-NAHHAS SA; MAKRAM TS: Improvement of the biological performance of oral anticoagulant drugs. Part 1. Warfarin. Pharmazie (1997) 52 (8):627–631.
   Google Scholar
• SERLIN MJ, BRECKENRIDGE AM: Drug interactions with warfarin. Drugs (1983) 25(6):610–620.
   PubMed Web of Science ®Google Scholar
• KAISER B, CALLAS D, WALENGA JM, FAREED J: Synthetic and recombinant antithrombin drugs. Exp. Opin. Invest. Drugs (1998)7(6):963–985.
   PubMedGoogle Scholar
• MARKWARDT F: Pharmacology of hirudin: one hundred years after the first report of the anticoagu-lant agent in medicinal leeches. Biomed. Biochim. Acta (1985) 44(7-8):1007–1113.
   PubMedGoogle Scholar
• KIKUMOTO R, TAMAO Y, OHKUBO K et al: Thrombin inhibitors 3. Carboxyl-containing amide derivatives of Na-substituted L-arginine. J. Med. Chem. (1980) 23(12):1293–1299.
   PubMed Web of Science ®Google Scholar
• •Description of the development of argatroban.
   Google Scholar
• MARKWARDT F, FINK G, KAISER B et al.: Pharma-cological survey of recombinant hirudin. Pharmazie (1988) 43(3):202–207.
   PubMed Web of Science ®Google Scholar
• TALBOT M: Recombinant hirudin: a new prospect in thrombosis. Curr. Stud. Hematol Blood Transfus. (1991) 58(Biotechnol. Plasma Proteins):1–7.
   Google Scholar
• TALBOT MD, AMBLER J, BUTLER KD et al.: Recombinant desulfatohirudin (CGP 39393). Anticoagulant and antithrombotic properties in vivo. Thromb. Haemostasis (1989) 61(1):77–80.
   PubMed Web of Science ®Google Scholar
• ••Review of the preclinical aspects of recombinant hirudin.
   Google Scholar
• VERSTRAETE M, NURMOHAMED M, KIENAST J et al: Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. J. Am. Coll. Cardiol. (1993) 22(4):1080–1088.
   PubMed Web of Science ®Google Scholar
• ••The first demonstration of recombinant hirudin in man.
   Google Scholar
• ERIKSSON BI, EKMAN S, BAUR M et al.: Regional block anaesthesia versus general anaesthesia. Are different antithrombotic drugs equally effective in patients undergoing hip replacement? Retrospective analysis of 2354 patients undergoing hip replacement receiving either recombinant hirudin, unfractionated heparin or enoxaparin. Thromb. Haemostasis (1997) (Suppl.):487–488.
   Google Scholar
• ERIKSSON BI, WILE-JORGENSEN P, KALEBO P et al: A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. New Engl. J. Med. (1997) 337:1329–1335.
   PubMed Web of Science ®Google Scholar
• ••Demonstration of the use of recombinant hirudin insituations of DVT.
   Google Scholar
• TOPOL EJ, FUSTER V, HARRINGTON RA et al.: Recombi-nant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. Circula-tion (1994) 89:1557–1566
   PubMed Web of Science ®Google Scholar
• SERRUYS PW, HERRMAN J-PR, SIMON R: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. New Engl. J. Med. (1995) 333:757–763.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ: Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Ha Investigators Random-ized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation (1994) 90(1):1631–1637.
   PubMedGoogle Scholar
• Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO) fib Investigators A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. New Engl. J. Med. (1996) 335:775–782.
   PubMed Web of Science ®Google Scholar
• METZ BK, WHITE HD, GRANGER CB et al. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-Ilb) Investigators et al. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrino-lytic therapy for acute myocardial infarction: results from the GUSTO-fib trial. J. Am. Coll. of Cardiol. (1998) 31:1493–1498.
   Google Scholar
• ••Description of the pivotal GUSTOIIb trial with recombinanthirudin.
   Google Scholar
• ANTMAN EM: TIMI 9A Investigators - Hirudin in acutemyocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMO 9A Trial. Circulation (1994) 90\(Part 1) 1624–1630.
   Google Scholar
• ANTMAN EM: TIMI 9B Investigators-Hirudin in acutemyocardial infarction: thrombolysis and thrombin inhibition in Myocardial Infarction (TIMO 9B Trial. Circulation (1996) 94:911–921.
   PubMed Web of Science ®Google Scholar
• KLONER RA, SHOOK T, ANTMAN EM: TIIVII-9B Investiga-tors et al.-Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TINII-9B. Circulation (1998) 97:1042–1045.
   Google Scholar
• •Description of the pivotal TIMI-9b trial with recombinant hirudin.
   Google Scholar
• VERSTRAETE M: Direct thrombin inhibitors. Appraisal of the antithrombotic/hemorrhagic balance. Thromb. Haemostasis (1997) 78(1)357–363.
   Google Scholar
• •A concise review of the clinical trial data on hirudin up to that date.
   Google Scholar
• HERMANN J-PR, KUTRYK MJB, SERRUYS PW: Clinical trials of direct thrombin inhibitors during invasive procedures. Thromb. Haemostasis (1997) 78(1)367–376.
   Google Scholar
• ANDREOTTI F: The TIMI 9b and GUSTO fib trials and the'thrombin hypothesis'. J. Thromb. Thrombolysis (1997) 4(3/0311–313.
   Google Scholar
• ANAND SS, YUSUF S, POGUE J et al.: Long-term oralanticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarc-tion: Organization to Assess Strategies for Ischemic Syndromes (OASIS) pilot study results. Circulation (1998) 98(10:1064–1070.
   PubMedGoogle Scholar
• NEUHAUS K-L, NIEDERER W et al.: r-Hirudin and front-loaded alteplase in acute myocardial infarction: results of the HIT (Hirudin for Improvement of Thrombolysis) study. Eur. HeartJ (1993) 14 (Suppl.):106.
   Google Scholar
• ZEYMER U, VON ESSEN R, TEBBE U et al.: Recombinanthirudin and front-loaded alteplase in acute myocardial infarction: final results of a pilot study: HIT-I (Hirudin for the Improvement of Thrombolysis). Eur. Heart J. (1995) 16(Suppl. D):22–27.
   Google Scholar
• NEUHAUS K-L, VON ESSEN R, TEBBE U et al.: Safetyobservations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis Study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Circula-tion (1994) 90(0:1638–1642.
   PubMedGoogle Scholar
• MOLHOEK P, TEBBE U, LAARMAN et al.: Hirudin for theimprovement of thrombolysis with streptokinase in patients with acute myocardial infarction. Results of the HIT-4 study. Circulation (1997) 96(Suppl.):205–221.
   Google Scholar
• WHITE HD, AYLWARD PE, FREY MJ: Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators-Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation (1997) 96:2155–2161.
   PubMed Web of Science ®Google Scholar
• VERMEER F, VAHANIAN A, FELS PW et al.: Intravenous argatroban versus heparin as co-medication to alteplase in the treatment of acute myocardial infarc-tion; preliminary results of the ARGAMI pilot study. J. Am. Coll Cardiol (1997) 29 (Suppl. A):185–186.
   Google Scholar
• SIMOONS ML, VAN MILTENBURG A, SCHEFFER MG et al: Anticoagulant properties of efegatran, a direct thrombin inhibitor in patients with unstable angina. Eu. Heart J. (1994) 15 (Suppl.) :120.
   Google Scholar
• SIMOONS M, LENDERINK T, SCHEFFER M et al.: Efegatran, a new direct thrombin inhibitor: safety and dose response in patients with unstable angina. Circulation ( 1994) 90\(Part 2):231.
   Google Scholar
• GERSHONY G, MANN DL, CHRISTIE JR: ESCALAT Investi-gators et aL-Clinical hemorrhage and coagulation parameters following therapy with efegatran versus heparin in the ESCALAT Trial. J. Am. Coll. Cardiol. (1997) 29(Suppl. A):413.
   Google Scholar
• ••A comprehensive examination of one of the newer lowmolecular weight synthetic thrombin inhibitors.
   Google Scholar
• MILLER JM, BARSNESS GW, LEIMBERGER JD et al.: Direct thrombin inhibition with efegartran does not suppress heightened thrombin generation during thrombolysis for acute myocardial infarction. Circula-tion (1997) 96 (Suppl.):534.
   Google Scholar
• TEGER-NILSSON A-C, ERIKSSON U, GUSTAFSSON D et al: Phase I studies on inogatran, a new selective thrombin inhibitor. J. Am. College Cardiol. (1995) (Spec. issue):117–118.
   Google Scholar
• Thrombin Inhibition in Myocardial Ischaemia (TRIM) Study Group-A low molecular weight, selective thrombin inhibitor, inogatran, vs. heparin, in unstable coronary artery disease in 1209 patients: a double-blind, randomized, dose-finding study. Eu. Heart J. (1997) 18:1416–1425.
   Google Scholar
• ERIKSSON H, ERIKSSON UG, FRISON L et al: Intravenous treatment of acute deep venous thrombosis with melagatran, a synthetic low molecular weight thrombin inhibitor. Thromb. Haemost. (1997) (Suppl.) :591.
   Google Scholar
• GAST A, TSCHOPP TB, SCHMID G et al.: Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombi-nant hirudin and heparin in human plasma. Blood Coag. Fibrinolysis (1994) 5:879–887
   PubMed Web of Science ®Google Scholar
• BOUNAMEAUX H, EHRINGER H, HULTING J: ADVENT Investigators et al.-An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46–6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis: results of the European multicenter ADVENT trial. Thromb. Haemost (1997) 78:997–1002.
   Google Scholar
• ZHANG M, BAILEY DL, BASTIAN JA et al.: Dibasic benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors 2. Sidechain optimization and demonstration of in vivo efficacy. Bioorg. Med. Chem. Lett. (1999) 9(5):775–780.
   PubMed Web of Science ®Google Scholar
• ALLEN M, ABEL SM., BARBER CG et al.: The discovery of UK-156,406 - an orally active thrombin inhibitor. Book of Abstracts, 215th ACS National Meeting, Dallas, American Chemical Society, Washington, DC., March 29-April 2 (1998):MEDI200.
   Google Scholar
• SANDERSON PEJ: Book of Abstracts 214th American Chemical Society National Meeting, Las Vagas, Navada, USA, September 7–11 (1997).
   Google Scholar
• SANDERSON PEJ, LYLE TA, CUTRONA KJ et al.: Effica-cious, Orally Bioavailable Thrombin Inhibitors Based on 3-Aminopyridinone or 3-Aminopyrazinone Acetamide Peptidomimetic Templates. J. Med. Chem. (1998) 41 (23):4466–4474.
   PubMed Web of Science ®Google Scholar
• COOK JJ, GARDELL SJ, HOLAHAN M et al.: Antithrom-botic efficacy of thrombin inhibitor L-374,087: intrave-nous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis. J. Pharmacol. Exp. Ther. (1999) 289(1):503–510.
   PubMed Web of Science ®Google Scholar
• •A description of the discovery of novel orally available thrombin inhibitors.
   Google Scholar
• SANDERSON PEJ: The design of orally active pyridi-none and pyrazinone acetamide thrombin inhibitors. Book of Abstracts, 215th ACS National Meeting, Dallas, March 29-April 2 (1998):MEDI199.
   Google Scholar
• REBELLO SS, MILLER By, BASLER GC et al.: CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. J. Cardiovasc. Pharmacol. (1997) 29(2)240–249.
   Google Scholar
• DE NANTEUIL G, VERBEUREN TJ: S 18326: a thrombin inhibitor that shows potential for oral treatment of thromboembolic disorders. Exp. Opin. Invest. Drugs (1999) 8(2):173–180.
   PubMedGoogle Scholar
• GREINACHER A, VOLPEL H, JANSSENS U et al.: Recombi-nant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation (1999) 99(0:73–80.
   PubMedGoogle Scholar
• ••Describes the effective use of recombinant hirudin in HIT.
   Google Scholar